Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Cactus Inc. Class A Common Stock (WHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Cactus Inc. Class A Common Stock — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Cactus Inc. Class A Common Stock trades at $62.37 (market cap $5.14B). The key difference: Travere Therapeutics Inc. Common Stock and Cactus Inc. Class A Common Stock are close in size by market cap, and Cactus Inc. Class A Common Stock pays a 0.94% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Cactus Inc. Class A Common Stock for 0 Days on average.
| TVTX | WHD | |
|---|---|---|
Market Cap | $4.88B | $5.14B |
Volume | 1,668,577 | 634,348 |
Sector | Health | Energy |
52-Week High | $67.52 | $73.73 |
52-Week Low | $26.79 | $35.26 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $5.01B | $4.83B |
Dividend Yield | — | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Cactus Inc. Class A Common Stock
Cactus Inc. designs, manufactures, and rents wellhead and pressure control equipment for oil and gas drilling, completion, and production, operating under the Cactus Wellhead brand.
Read more on WHD →
